Ovarian cancer screening has been described in scientific reports [1] [2] [3] [4] , as well as in reviews and summaries. Scientific reports contain the facts of a study, while reviews and summaries present interpretations. Presented here are scientific reports which add considerable information to the area of early stage ovarian cancer detection and the application of this detection to ovarian cancer screening. In the present reports:
benefits accruing to women who participate in routine ovarian cancer screening and receive normal test results [11] .
Koshiyama and collaborators present current issues that are related to ovarian cancer and screening. They report that the efficacy of ovarian cancer screening may be higher in Asia than in Europe and the USA. These investigators review the re-analysis of PLCO screening data when cancers presenting more than one year after screening are excluded and show a significant survival benefit in the PLCO screening. They highlight their views by considering the difficulties of detecting Type II ovarian carcinomas [12] .
Chris Smith examines the effects that ovarian cancer has on patients and their families. The rigors of treatment conspire with the inevitability of recurrence in the eyes of this first year resident in Obstetrics and Gynecology. He postulates that in the absence of effective therapies, early detection holds the greatest promise [13] .
Fred Ueland relates the 50 year history of biomarkers and ultrasound in the context of ovarian cancer. He emphasizes the serial application of both biomarkers and ultrasound. Importantly, he looks to what the future may bring with regard to the utilization of biomarkers and ultrasound in routine patient exams [14] .
Taken together, these authors have provided both original data and overviews of ovarian cancer screening studies that enhance the present interpretation of this type of screening.
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